Novo Nordisk Eli Lilly

Novo Nordisk, CagriSema

Investors are growing anxious about Novo Nordisk’s silence since disappointing CagriSema weight loss drug results

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

Reuters · 2d

Novo Nordisk's next-gen obesity drug Cagrisema: investors seek answers

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema amid a lack of clarity over trial results that hammered its shares in December.

The New York Times · 1d

Novo Nordisk Annual Sales Jump on Higher Demand for Obesity Drugs

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower growth this year.

Wegovy sales double to boost Novo Nordisk's 4th quarter

Reuters · 1d

Wegovy sales double to boost Novo Nordisk's fourth quarter as growth set to slow

Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the fourth quarter, with analysts and investors describing the results as "good enough" to ease nerves about stiff competition from rival Eli Lilly.

Business Insider · 1d

NVO Earnings: Novo Nordisk Jumps on Healthy Sales Beat Driven by Wegovy

American depositary receipts (ADRs) of Novo Nordisk (NVO) jumped over 4% in pre-market trading this morning after reporting a healthy sales

The Wall Street Journal on MSN · 1d

Novo Nordisk Expects Slowing Sales Growth This Year

The Danish pharmaceutical company expects sales growth to slow this year as capacity constraints, intensifying competition and pricing pressure drag on sales of its blockbuster weight-loss and diabetes drugs.

9hon MSN

Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected

Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.

FierceBiotech7h

Eli Lilly's next R&D focus: Testing incretin meds in neuro, immunology fields

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

11hon MSN

Diabetes and obesity drugs fuel Eli Lilly profit in the final quarter of 2024

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

12hon MSN

Eli Lilly beats on earnings even as weight loss, diabetes drug sales fall short

Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...

1don MSN

Why Novo Nordisk Stock Is Soaring Today

Shares of Novo Nordisk ( NVO 4.37%) were moving higher on Wednesday. The company's stock gained 4.9% as of 1:50 p.m. ET, but ...

Eli Lilly (LLY) Stock Eyes Price Breakout as Q4 Results Loom

Eli Lilly (LLY) investors should expect fireworks this week as the pharma giant prepares to drop its bombshell Q4 2024 ...

Health Care Climbs After Lilly Earnings - Health Care Roundup

Health-care companies rose after strong earnings from one obesity-drug maker. Eli Lilly shares rose after it reiterated its forecast for 32% 2025 revenue growth, amid rising demand for its Zepbound ...

10h

Eli Lilly reports mixed earnings, increases 2025 guidance

Lilly upgraded its 2025 guidance to between $58 billion to $61 billion, slightly higher than Wall Street expectations by $1 ...

10hon MSN

Eli Lilly’s Disappointing Quarter Was Already Baked In

Eli Lilly ripped off the bandage when it reported preliminary fourth-quarter results in mid-January, getting the bad news out ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results